Latest | Instant Finance & Market News_第571页 | NewTimeSpace

11:18

【Xtrackers MSCI Korea UCITS ETF(02848.HK) surged intraday, up more than 3%.】Xtrackers MSCI Korea UCITS ETF(02848.HK) surged more than 3% intraday after the opening bell on 7 January; the fund has gained over 100% in the past year and remains in a firm uptrend.

Tag： NewTimeSpace 02848.HK Xtrackers MSCI Korea UCITS ETF

11:10

【Csop Nikkei 225 Index Etf(03153.HK) eases 0.84%, snapping its four-day rally.】Csop Nikkei 225 Index Etf(03153.HK) slipped 0.84%, halting its recent surge and ending a four-day winning streak.

Tag： NewTimeSpace 03153.OF Csop Nikkei 225 Index

11:07

【Hwabao WP CSI Financials Theme ETF(159851) Falls Nearly 2% in Morning Trading, Latest Scale Reaches 10.881 Billion Yuan】As of 11:06 on January 7, 2026, FinTech ETF (159851) fell 1.79%, with the latest quote at 0.88 yuan.

Tag： FinTech ETF 159851.SZ ETF

10:53

【Guotai CSI Semiconductor Material Equipment Theme ETF (159516) Surges Over 6% in Morning Trading, Aiming for Third Consecutive Gain】As of 10:49 on January 7, 2026, Semiconductor Equipment Materials ETF (159516) rose 6.14%, aiming for its third consecutive gain, with the latest price at 1.8 yuan.

Tag： Semiconductor Equipment Materials ETF 159516.SZ ETF

10:39

【GF CSI Innovative Drugs Industry ETF (515120) Rises Over 1% in Morning Trading, Aiming for Third Consecutive Gain】As of 10:31 on January 7, 2026, Innovation Drug ETF (515120) rose 1.07%, aiming for its third consecutive gain, with the latest price at 0.66 yuan.

Tag： Innovation Drug ETF 515120.SH ETF

10:19

【Hong Kong tech stocks fell across the board, with the iShares Hang Seng TECH ETF down 1.5% and iShares Hang Seng TECH (03067.HK) sliding more than 2%.】January 7 saw Hong Kong tech stocks tumble broadly, with the Hang Seng TECH Index sliding 1.5%. Wind data show that as of 10:17 a.m. the iShares Hang Seng TECH ETF (03067.HK) had sunk 2.28%.

Tag： NewTimeSpace 03067.OF

10:19

【Huatai-PB CSI Rare earth industry ETF(516780) Up 1.67% in Morning Trading】As of 10:11 on January 7, 2026, Rare Earth ETF (516780) rose 1.67%, aiming for its ninth consecutive gain, with the latest price at 1.88 yuan.

Tag： Rare Earth ETF 516780.SH ETF

10:08

【Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) surges over 2%, focusing on Hong Kong-listed biotech companies.】the Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) staged a strong morning session. As of 10:05, the fund had jumped more than 2%, extending its five-day gain to 8.35%. It is now on track for a fourth consecutive daily advance.

Tag： NewTimeSpace Chinaamc Hang Seng Hong Kong Biotech Index ETF 03069.HK

10:01

【Guotai CES Semiconductor Chip Industry ETF (512760) Rises Nearly 2%, Aiming for Third Consecutive Gain】As of 09:55 on January 7, 2026, Chip ETF (512760) rose 1.91%, aiming for its third consecutive gain, with the latest price at 1.76 yuan.

Tag： Chip ETF 512760.SH ETF

09:48

【China-Korea Semiconductor ETF (513310) Surges Over 6%, Aiming for Third Consecutive Gain】As of 09:43 on January 7, 2026, The China-Korea Semiconductor ETF (513310) jumped 6.10%, aiming for its third consecutive gain, with the latest price at 3.13 yuan.

Tag： The China-Korea Semiconductor ETF 513310.SH ETF

09:42

【Global X Ai Infrastructure Etf (03401.HK)eads Hong Kong equity ETFs, surging over 3% in early trading.】Global X Ai Infrastructure Etf (03401.HK) surged 3.28%, leading Hong Kong stock equity ETFs. The fund has gained 7.19% over the past five trading days.

Tag： NewTimeSpace 03401.HK

08:50

【AI medical unicorn Hangzhou Diagens Biotechnology Co., Ltd. makes a second attempt to list on the Hong Kong Stock Exchange: backed by the world's first medical imaging large model, with a 30.6% market share ranking first】Hangzhou Diagens Biotechnology Co., Ltd. once again submitted an application for listing to the Hong Kong Stock Exchange on January 6. Relying on the world's largest parameter iMedImageTM medical imaging large model, the company firmly ranks as the leader in China's chromosome karyotype analysis market with a 30.6% market share.

Tag： Hangzhou Diagens Biotechnology Co., Ltd.IPO submission AI medical care

08:20

【GF SEC(01776.HK): Plans to place 219 million H-shares and issue HK$2.15 billion convertible bonds, with net proceeds exceeding HK$6.1 billion】After obtaining the general mandate from the shareholders' general meeting on November 26, 2025, GF SECannounced on January 6, 2026 that it intends to place 219 million new H-shares at HK$18.15 per share and issue HK$2.15 billion zero-coupon convertible bonds due 2027 with an initial conversion price of HK$19.82 per share. The total funds raised from the two items are expected to be approximately HK$6.113 billion, and the net proceeds are intended to be fully used for capital increase to overseas subsidiaries to support the development of international business. The placed shares account for approximately 12.87% of the existing H-shares. If the convertible bonds are fully converted, approximately 108 million H-shares can be issued, accounting for approximately 6.37% of the existing H-shares. The completion of both issuances is subject to the fulfillment of conditions such as listing approval and filing with the China Securities Regulatory Commission.

Tag： GF Securities 01776.HK New Share Placing

08:08

【HUTCHMED(00013.HK): Sostarlimab Phase III study successful; plans to submit new drug application to NMPA in the first half of 2026】HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.

Tag： HUTCHMED 00013.HK Sostarlimab

07:58

【APEX ACE HLDG(06036.HK): US$3.5 million invested in key person insurance policy, triggering disclosure requirements under listing rules】APEX ACE HLDG (6036), through its indirectly wholly-owned subsidiary Avite International, paid a premium of US$3.5 million (approximately HK$27.3 million) to HSBC Life on January 5, 2026 to purchase a whole life insurance policy for Mr. Li, the executive director and chairman. This key person insurance policy constitutes a discloseable transaction under the listing rules. On the same day, the borrower confirmed its acceptance of a HK$215.8 million revolving trade loan facility provided by HSBC. The financing terms stipulate that if Mr. Li ceases to serve as chairman and chief executive officer, it will constitute a default. The board of directors believes that the policy can provide financial protection for the Group, and the death benefit may be higher than the premium expenditure in the future.

Tag： APEX ACE HLDG 06036.HK insurance policy

07:23

【J&T Express-W(01519.HK): Q4 package volume increased by 14.5% year-on-year, and the Southeast Asian market increased by over 70% year-on-year】J&T Express (1519) announced its operating data for the fourth quarter and the full year of 2025. The annual package volume reached 30.129 billion, an increase of 22.2% year-on-year. Among them, the Southeast Asian market grew by 67.8% to 7.659 billion, and the new market grew by 43.6% to 404 million. The total package volume in the fourth quarter was 8.461 billion, an increase of 14.5% year-on-year. As of the end of 2025, the number of outlets in Southeast Asia increased to 10,800, and the number of trunk vehicles increased to 5,800. The company plans to hold a conference call on January 7, 2026, and the relevant data is unaudited.

Tag： J&T Express-W 01519.HK Going Global

07:12

【SAIMO(02571.HK): Deemed Disposal of 49% Interest in Subsidiary, Post-investment Consolidation Continues】Beijing Saimo Technology (2571) announced that it will introduce investors to inject RMB12.0098 million into its subsidiary Zhejiang Saimo in exchange for 49% equity, reducing its stake to 51% while maintaining consolidation. The valuation is approximately RMB12.116 million using the asset-based approach. The transaction constitutes a discloseable transaction under Listing Rules, with the cash portion to be used for R&D and no gain or loss expected to be recognized.

Tag： SAIMO 02571.HK Capital Injection

18:27

【Weimob Inc. (02013.HK): Enters Business Cooperation with Taobao Flash Sale to Co-build Local Retail Solutions】Weimob Inc. (02013.HK) announced that its subsidiary has signed a strategic cooperation agreement with Taobao Flash Sale, the local lifestyle service platform under Alibaba Group. The two parties will carry out cooperation in scenarios such as instant retail ecosystem co-construction, member integration, AI and data operations, facilitating Weimob’s clients to operate on the Taobao Flash Sale platform and expanding the business space of merchant solutions.

Tag： Weimob Inc.02013.HK Market Share Cooperation

17:36

【Yuexiu Property Company Limited (00123.HK): Wins Residential Land Parcel in Shanghai Pudong New Area with RMB 2.561 Billion】Yuexiu Property Company Limited (00123.HK) announced that on January 6, 2026, its subsidiary (in which it holds a 95% stake) successfully won a residential land parcel in Pudong New Area, Shanghai, with a bid price of RMB 2.561 billion. The land parcel covers an area of approximately 26,931.62 square meters, with a gross floor area (GFA) of about 67,329.05 square meters.

Tag： Yuexiu Property Company Limited 00123.HK Major Project

17:13

【HISENSE HA(00921.HK): Subsidiaries Subscribe to COFCO Trust Wealth Management Products with RMB1.855 Billion】HISENSE HA disclosed that three of its subsidiaries have jointly subscribed to multiple wealth management products issued by COFCO Trust with a total of RMB1.855 billion of the group’s idle own funds between July 16, 2025, and January 6, 2026. All products are medium-to-low risk fixed-income instruments, investing in debt assets such as deposits and bonds. The move aims to improve capital utilization efficiency without affecting the company’s daily operations or core business development.

Tag： HISENSE HA 00921.HK

Scan QR Code

Download App